论文部分内容阅读
１８ 例带配子体的恶性疟患者随机分为２ 组： 双氢青蒿素组１０ 例， 口服５ ｄ 疗程总量３６０ ｍｇ ； 奎宁组８ 例， 口服７ ｄ 疗程总量１０ ５００ ｍｇ 。全部患者每天涂血片计算配子体密度， 于给药当天（Ｄ０） ， 药后４ 、７ 、１０ 、１４ 、２１ 和２８ ｄ （Ｄ４ 、Ｄ７ 、Ｄ１０ 、Ｄ１４ 、Ｄ２１ 、和Ｄ２８） 取血作大劣按蚊感染试验。患者血中配子体转阴时间， 双氢青蒿素组为２１ ．８ ±５ ．２ ｄ ； 奎宁组为３１ ．５ ±８ ．７ ｄ 。按蚊感染试验结果： 双氢青蒿素组有４ 例在Ｄ０Ｄ４ 、Ｄ７ 、Ｄ１０ 、Ｄ１４ 均未能感染按蚊； 其余６ 例于Ｄ０ 、Ｄ４ 、Ｄ７ 、Ｄ１０ 、Ｄ１４ 、Ｄ２１ 按蚊感染阳性例数为６／６ 、６／６ 、６／６ 、２／６ 、０／６ 和０／６ 。奎宁组Ｄ０ 、Ｄ４ 、Ｄ７ 、Ｄ１０ 、Ｄ１４ 、Ｄ２１ 和Ｄ２８ 按蚊感染阳性例数为４／８ 、８／８ 、８／８ 、８／８ 、８／８ 、２／８ 和０／８ 。这表明双氢青蒿素５ ｄ 总量３６０ ｍｇ 对恶性疟原虫有性生殖期发育有明显抑制作用， 对生理上未成熟的配子体， 可中断其发育。
Eighteen patients with falciparum malaria with gametocytes were randomly divided into two groups: 10 patients in the dihydroartemisinin group, a total of 360 mg in a 5-day course of oral administration, 8 patients in the quinine group, and a total of 10 500 mg in a 7-day course of oral administration. All patients took blood tablets every day to calculate the gametocyte density. On the day of dosing (D0), blood was taken at 4, 7, 10, 14, 21, and 28 d (D4, D7, D10, D14, D21, and D28). Inferior mosquito infection test. The time during which the gametophyte was negative in the patient’s blood was 21% in the dihydroartemisinin group. 8 ±5. 2 d ; quinine group 31. 5 ±8 . 7 d. Anopheline Infection Test Results: Four patients in the dihydroartemisinin group were unable to infect Anopheles mosquitoes on D0D4, D7, D10, and D14; the remaining 6 patients were positive for Anopheles mosquitoes on D0, D4, D7, D10, D14, and D21. The numbers are 6/6, 6/6, 6/6, 2/6, 0/6 and 0/6. The number of positive cases of Anopheles mosquitoes in the quinine group (D0, D4, D7, D10, D14, D21, and D28) was 4/8, 8/8, 8/8, 8/8, 8/8, 2/8, and 0/8. . This shows that dihydroartemisinin for a total of 360 mg for 5 d significantly inhibited the reproductive development of Plasmodium falciparum and disrupted the development of physiologically immature gametophyte.